Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm

March 13, 2025 12:15 PM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy.Olayinka Oyebola & Co. has worked diligently to complete...

Read more

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

March 13, 2025 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster...

Read more

Biovica Q3 Interim report Nov 2024 - Jan 2025

March 13, 2025 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Quarterly sales doubled, expanding market potential exponentiallySEK tQ3 24/25Q3 23/24May-Jan 24/25May-Jan 23/24Full year 23/24Net sales2,2611,0756,2875,3917,290Operating profit (loss)-22,183-27,848-65,499-85,355-126,845Profit (loss) for the period-22,816-27,343-66,857-85,292-124,823Earnings per share, after dilution-0.23-0.44-0.74-1.66-2.14Average number of shares during the...

Read more

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"

March 12, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content,...

Read more

Notice of Annual General Meeting in FluoGuide A/S

March 12, 2025 5:15 AM

KØBENHAVN, DK / ACCESS Newswire / March 12, 2025 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64 38 (the "Company" or "FluoGuide"), to be held on27 March 2025 at 2.00 PM (CET)at the Company's premises, Titanhus, Titangade 9-13, meeting room - Kronos, DK-2200 Copenhagen N, Denmark.The agenda for the Annual General Meeting is as follows:1....

Read more

Biovica and Outcomes4Me Partner to Support Metastatic Breast Cancer Patients to Better Understand the Effectiveness of their Treatment

March 12, 2025 3:30 AM

UPPSALA, SE / ACCESS Newswire / March 12, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Today, Biovica, a leader in blood-based cancer monitoring, announces a partnership with Outcomes4Me, the developer of the leading direct-to-patient empowerment platform that provides personalized, evidence-based navigation to people diagnosed with cancer. Together, Biovica and Outcomes4Me will support post-menopausal patients with...

Read more

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

March 11, 2025 8:05 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it has appointed Craig L. Tendler, M.D. to its Board of Directors effective March 10, 2025."We are honored and thrilled to have Craig join our Board of Directors. His extensive experience in creating and overseeing development plans, including...

Read more

Aspira Women's Health Announces Closing of $1.37 Million Private Placement of Convertible Notes

March 11, 2025 8:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into a securities purchase agreement dated March 6, 2025, pursuant to which the Company has sold and issued an aggregate principal amount of $1.37 million in the form of Senior Secured Convertible Promissory Notes due March 6,...

Read more

Biolog Introduces the RhizoPlate Line: A Game-Changer for Sustainable Agriculture

March 11, 2025 4:00 AM

Biolog, Inc. - a leading provider of phenotypic cellular profiling products, multi-omic microbial identification services, and tools for cultivating anaerobes - is excited to announce the launch of its new RhizoPlate™ line of microplates for rapidly assessing nitrogen fixation and phosphate solubilization in soil bacteria. For companies focused on developing new products for sustainable agriculture, these plates represent an unprecedented...

Read more

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

March 10, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or...

Read more

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

March 10, 2025 9:00 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat on Tuesday, March 18, 2025 at 8:30 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA.In addition to the presentation,...

Read more

Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board

March 10, 2025 8:00 AM

Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, today announced the appointment of Dr. Deepak L. Bhatt as a scientific advisor."We are pleased to welcome Dr. Deepak L. Bhatt, a noted interventional cardiologist, to our Scientific Advisory Board," said Reason, Chief Executive Officer and Co-Founder of Repair...

Read more

Biovica Signs New Work Order with US Biotech Company for TKa Testing Services

March 10, 2025 3:15 AM

UPPSALA, SE / ACCESS Newswire / March 10, 2025 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in blood-based cancer monitoring, has secured a new work order (WO) valued at SEK 2.5 million for TKa testing services within its Pharma Services business. This marks the third work order signed with this customer, bringing the total value of the three orders to SEK 7 million.The customer, a clinical-stage biotech...

Read more

BioLumic Launches World's First Commercial Light-Activated Seed Traits

March 6, 2025 2:30 PM

BioLumic, the world's only company programming seed traits with light, has launched its first commercial Trait Activation System at Gro Alliance's seed production facility in Cuba City, Wisconsin. This milestone brings the BioLumic proprietary light-based Genetic Expression Trait (xTrait™) technology to the global seed industry, enabling new opportunities for enhanced crop performance. BioLumic's trait activation system treats inbred corn lines...

Read more

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

March 6, 2025 8:30 AM

Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About Barinthus Biotherapeutics plcBarinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases...

Read more

Biovica Signs Agreement With Eurobio Scientific Covering 60 Percent of European Market

March 5, 2025 2:10 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, has signed a collaboration agreement with Eurobio Scientific, a leading French group in in vitro specialty medical diagnostics and life sciences, for DiviTum® TKa in Austria, Benelux, France, Germany, Switzerland and the UK. The scope of the agreement covers 60 percent of the total market potential identified as key European markets for...

Read more

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

March 4, 2025 9:00 AM

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular...

Read more

BRK Technology Accelerates Sustainable Energy Initiatives, Engages With Industry Leaders

March 4, 2025 9:00 AM

BRK Technology is advancing its mission to revolutionize the heavy machinery fuel sector with eco-friendly biofuels. The company is actively collaborating with prominent industry players to explore innovative solutions that enhance efficiency and reduce environmental impact.Recent discussions with leading firms in the industrial and energy sectors highlight BRK Technology's commitment to sustainable progress. These strategic engagements align...

Read more

uBriGene Biosciences Submits Drug Master File for iPSC Reprogramming mRNA-LNP Kit

March 4, 2025 7:00 AM

uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for its innovative iPSC Reprogramming mRNA-LNP Kit. This comprehensive regulatory submission details the manufacturing and characterizations of the iPSC Reprogramming mRNA-LNP Kit.The iPSC Reprogramming mRNA-LNP Kit represents a cutting-edge platform designed to reprogram somatic cells into induced...

Read more

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

March 4, 2025 7:00 AM

BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF) receptors. Using its proprietary EpiClick™...

Read more